- Home
- DT vs PCVX Comparison
DT vs PCVX Comparison
Compare DT & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DT | PCVX |
|---|---|---|
| Founded | 2005 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7B | 8.6B |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | DT | PCVX |
|---|---|---|
| Price | $40.71 | $52.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 26 | 4 |
| Target Price | $51.77 | ★ $88.25 |
| AVG Volume (30 Days) | ★ 5.6M | 1.2M |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 205.77 | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $1,698,683,000.00 | N/A |
| Revenue This Year | $21.74 | N/A |
| Revenue Next Year | $14.85 | N/A |
| P/E Ratio | $84.15 | ★ N/A |
| Revenue Growth | ★ 18.75 | N/A |
| 52 Week Low | $31.64 | $28.64 |
| 52 Week High | $57.55 | $65.00 |
Technical Indicators
Market Signals| Indicator | DT | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 67.39 | 36.53 |
| Support Level | $38.50 | $52.04 |
| Resistance Level | $41.02 | $56.04 |
| Average True Range (ATR) | 1.24 | 2.68 |
| MACD | 0.61 | -0.92 |
| Stochastic Oscillator | 95.32 | 32.17 |
Price Performance
Historical ComparisonAbout DT Dynatrace Inc.
Dynatrace is a software-as-a-service company that enables customers to monitor and analyze their information technology infrastructure, from servers to applications and Python scripts. Dynatrace's unified platform can ingest and analyze large amounts of machine-generated data in real time, allowing clients to optimize their business for service-level objectives and ensure uptime.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.